Fan Yujie,Qu Shuangquan.Research advances of NLRP3 inflammasome in lung injury[J].Journal of Clinical Pediatric Surgery,,():288-292.[doi:10.3760/cma.j.cn101785-202311050-017]
Research advances of NLRP3 inflammasome in lung injury
- Keywords:
- NLRP3 inflammasome; Pyroptosis; Lung injury
- Abstract:
- Common in clinical practices,lung injury may be roughly divided into chronic and acute lung injuries according to the development course of the disease.Inflammatory factors play an important role in the occurrence and development of chronic and acute lung injuries.Some researchers have reported that nucleotide-binding oligomerization domain-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome plays an important regulatory role.NLRP3 inflammasome is a high molecular protein complex located in cells.Responding to endogenous danger signals and damage stimuli,it is an important component of respiratory immunity.However,excessive activation of NLRP3 inflammasome leads to pyroptosis.A subsequent release of inflammatory factors induce a complex cascade of lung inflammation and ultimately cause tissue injury and lung dysfunction.This review summarized the roles of NLRP3 inflammasome in lung tissue inflammatory injury.It was intended to provide more effective treatments and research rationales for clinical management of lung injury.
References:
[1] Herrlich A.Interorgan crosstalk mechanisms in disease:the case of acute kidney injury-induced remote lung injury[J].FEBS Lett,2022,596(5):620-637.DOI:10.1002/1873-3468.14262.
[2] Wang ZH,Pu QQ,Huang CH,et al.Crosstalk between lung and extrapulmonary organs in infection and inflammation[J].Adv Exp Med Biol,2021,1303:333-350.DOI:10.1007/978-3-030-63046-1_18.
[3] Zhong WJ,Liu T,Yang HH,et al.TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury[J].Int J Biol Sci,2023,19(1):242-257.DOI:10.7150/ijbs.77304.
[4] Coll RC,Schroder K,Pelegrín P.NLRP3 and pyroptosis blockers for treating inflammatory diseases[J].Trends Pharmacol Sci,2022,43(8):653-668.DOI:10.1016/j.tips.2022.04.003.
[5] Seoane PI,Lee B,Hoyle C,et al.The NLRP3-inflammasome as a sensor of organelle dysfunction[J].J Cell Biol,2020,219(12):e202006194.DOI:10.1083/jcb.202006194.
[6] Swanson KV,Deng M,Ting JPY.The NLRP3 inflammasome:molecular activation and regulation to therapeutics[J].Nat Rev Immunol,2019,19(8):477-489.DOI:10.1038/s41577-019-0165-0.
[7] Lee S,Suh GY,Ryter SW,et al.Regulation and function of the nucleotide binding domain leucine-rich repeat-containing receptor,pyrin domain-containing-3 inflammasome in lung disease[J].Am J Respir Cell Mol Biol,2016,54(2):151-160.DOI:10.1165/rcmb.2015-0231TR.
[8] Zheng DP,Liwinski T,Elinav E.Inflammasome activation and regulation:toward a better understanding of complex mechanisms[J].Cell Discov,2020,6(1):36.DOI:10.1038/s41421-020-0167-x.
[9] Lu FF,Lan ZX,Xin ZQ,et al.Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases[J].J Cell Physiol,2020,235(4):3207-3221.DOI:10.1002/jcp.29268.
[10] Hoffman KW,Visoki E,Argabright ST,et al.Association between asthma and suicidality in 9-12-year-old youths[J].Brain Sci,2022,12(12):1602.DOI:10.3390/brainsci12121602.
[11] Leszczyńska K,Jakubczyk D,Górska S.The NLRP3 inflammasome as a new target in respiratory disorders treatment[J].Front Immunol,2022,13:1006654.DOI:10.3389/fimmu.2022.1006654.
[12] Hikichi M,Mizumura K,Maruoka S,et al.Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke[J].J Thorac Dis,2019,11(Suppl 17):S2129-S2140.DOI:10.21037/jtd.2019.10.43.
[13] Guo P,Li R,Piao TH,et al.Pathological mechanism and targeted drugs of COPD[J].Int J Chron Obstruct Pulmon Dis,2022,17:1565-1575.DOI:10.2147/COPD.S366126.
[14] Liu G,Philp AM,Corte T,et al.Therapeutic targets in lung tissue remodelling and fibrosis[J].Pharmacol Ther,2021,225:107839.DOI:10.1016/j.pharmthera.2021.107839.
[15] Markeli? I,Hlap?i$\check{\mathrm{C}}$ I,$\check{C}$eri A,et al.Activation of NLRP3 inflammasome in stable chronic obstructive pulmonary disease[J].Sci Rep,2022,12(1):7544.DOI:10.1038/s41598-022-11164-1.
[16] Wu D,Wang X,Gao Y,et al.Shenqi Wenfei Formula alleviates chronic obstructive pulmonary disease in rats with pulmonary qi deficiency syndrome by regulating NLRP3/GSDMD pyroptosis pathway[J].J South Med Univ,2023,43(9):1500-1508.DOI:10.12122/j.issn.1673-4254.2023.09.07.
[17] Wu YX,Di X,Zhao M,et al.The role of the NLRP3 inflammasome in chronic inflammation in asthma and chronic obstructive pulmonary disease[J].Immun Inflamm Dis,2022,10(12):e750.DOI:10.1002/iid3.750.
[18] Ma M,Li GY,Qi MH,et al.Inhibition of the inflammasome activity of NLRP3 attenuates HDM-Induced allergic asthma[J].Front Immunol,2021,12:718779.DOI:10.3389/fimmu.2021.718779.
[19] Xu WJ,Wang YM,Ma Y,et al.MiR-223 plays a protecting role in neutrophilic asthmatic mice through the inhibition of NLRP3 inflammasome[J].Respir Res,2020,21(1):116.DOI:10.1186/s12931-020-01374-4.
[20] Kalikkot Thekkeveedu R,Guaman MC,Shivanna B.Bronchopulmonary dysplasia:a review of pathogenesis and pathophysiology[J].Respir Med,2017,132:170-177.DOI:10.1016/j.rmed.2017.10.014.
[21] Shukla VV,Ambalavanan N.Recent advances in bronchopulmonary dysplasia[J].Indian J Pediatr,2021,88(7):690-695.DOI:10.1007/s12098-021-03766-w.
[22] Wang XY,Huo R,Liang ZJ,et al.Simvastatin inhibits NLRP3 inflammasome activation and ameliorates lung injury in hyperoxia-induced bronchopulmonary dysplasia via the KLF2-mediated mechanism[J].Oxid Med Cell Longev,2022,2022:8336070.DOI:10.1155/2022/8336070.
[23] Wang MR,Zhang F,Ning XM,et al.Regulating NLRP3 inflammasome-induced pyroptosis via Nrf2:TBHQ limits hyperoxia-induced lung injury in a mouse model of bronchopulmonary dysplasia[J].Inflammation,2023,46(6):2386-2401.DOI:10.1007/s10753-023-01885-4.
[24] Savin IA,Zenkova MA,Sen’kova AV.Pulmonary fibrosis as a result of acute lung inflammation:molecular mechanisms,relevant in vivo models,prognostic and therapeutic approaches[J].Int J Mol Sci,2022,23(23):14959.DOI:10.3390/ijms232314959.
[25] Cao W,Wang X,Li JL,et al.NLRP3 inflammasome activation determines the fibrogenic potential of PM2.5 air pollution particles in the lung[J].J Environ Sci (China),2022,111:429-441.DOI:10.1016/j.jes.2021.04.021.
[26] Liu JJ,Fan GQ,Tao NN,et al.Ginsenoside Rb1 alleviates bleomycin-induced pulmonary inflammation and fibrosis by suppressing central nucleotide-binding oligomerization-,leucine-rich repeat-,and pyrin domains-containing protein three inflammasome activation and the NF-κB pathway[J].Drug Des Devel Ther,2022,16:1793-1809.DOI:10.2147/DDDT.S361748.
[27] Zhou H,Zhang Q,Huang W,et al.NLRP3 inflammasome mediates silica-induced lung epithelial injury and aberrant regeneration in lung stem/progenitor cell-derived organotypic models[J].Int J Biol Sci,2023,19(6):1875-1893.DOI:10.7150/ijbs.80605.
[28] Mokrá D.Acute lung injury-from pathophysiology to treatment[J].Physiol Res,2020,69(Suppl 3):S353-S366.DOI:10.33549/physiolres.934602.
[29] Santa Cruz R,Villarejo F,Irrazabal C,et al.High versus low positive end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome[J].Cochrane Database Syst Rev,2021,3(3):CD009098.DOI:10.1002/14651858.CD009098.pub3.
[30] Tomazini BM,Maia IS,Cavalcanti AB,et al.Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19:the CoDEX randomized clinical trial[J].JAMA,2020,324(13):1307-1316.DOI:10.1001/jama.2020.17021.
[31] Liu T,Zhou Y,Li P,et al.Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation[J].Sci Rep,2016,6:39473.DOI:10.1038/srep39473.
[32] He YQ,Zhou CC,Yu LY,et al.Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms[J].Pharmacol Res,2021,163:105224.DOI:10.1016/j.phrs.2020.105224.
[33] Cai DS,Zhao Y,Yu F.Puerarin ameliorates acute lung injury by modulating NLRP3 inflammasome-induced pyroptosis[J].Cell Death Discov,2022,8(1):368.DOI:10.1038/s41420-022-01137-8.
[34] He Q,Hu D,Zheng FQ,et al.Investigating the nexus of NLRP3 inflammasomes and COVID-19 pathogenesis:unraveling molecular triggers and therapeutic strategies[J].Viruses,2024,16(2):213.DOI:10.3390/v16020213.
[35] Madurka I,Vishnevsky A,Soriano JB,et al.DFV890:a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function[J].Infection,2023,51(3):641-654.DOI:10.1007/s15010-022-01904-w.
[36] 上官雪娟,屈双权.儿童单肺通气研究进展[J].临床小儿外科杂志,2023,22(2):188-191.DOI:10.3760/cma.j.cn101785-202206049-017.Shangguan XJ,Qu SQ.Research advances of one-lung ventilation in children[J].J Clin Ped Sur,2023,22(2):188-191.DOI:10.3760/cma.j.cn101785-202206049ma.j.
[37] Luo GJ,Yao WF,He Y,et al.Ulinastatin prevents acute lung injury led by liver transplantation[J].J Surg Res,2015,193(2):841-848.DOI:10.1016/j.jss.2014.08.051.
[38] Hou L,Yang ZW,Wang ZK,et al.NLRP3/ASC-mediated alveolar macrophage pyroptosis enhances HMGB1 secretion in acute lung injury induced by cardiopulmonary bypass[J].Lab Invest,2018,98(8):1052-1064.DOI:10.1038/s41374-018-0073-0.
[39] Sugasawa Y,Yamaguchi K,Kumakura S,et al.The effect of one-lung ventilation upon pulmonary inflammatory responses during lung resection[J].J Anesth,2011,25(2):170-177.DOI:10.1007/s00540-011-1100-0.
Memo
收稿日期:2023-11-30。
基金项目:湖南省自然科学基金面上项目(2023JJ30325)
通讯作者:屈双权,Email:shuangquanqu@126.com